

# Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF- $\kappa$ B blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with *MYD88* L265P mutation

Ivan Dlouhy,<sup>1,2\*</sup> Marc Armengol,<sup>3\*</sup> Clara Recasens-Zorzo,<sup>2</sup> Marcelo L Ribeiro,<sup>3,4</sup> Patricia Pérez-Galán,<sup>2</sup> Francesc Bosch,<sup>5</sup> Armando López-Guillermo<sup>1,2#</sup> and Gaël Roué<sup>3#</sup>

**Correspondence:** G. Roué  
[groue@carrerasresearch.org](mailto:groue@carrerasresearch.org)

**Received:** August 22, 2022.

**Accepted:** August 22, 2022.

<https://doi.org/10.3324/haematol.2022.281988>

©2022 Ferrata Storti Foundation

Published under a CC BY-NC license



Erratum to ms. HAEMATOL/2020/278258. “Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF- $\kappa$ B blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with *MYD88* L265P mutation” *Haematologica*. 2021 Oct 1;106(10):2749-2753. doi: 10.3324/haematol.2020.278258. PMID: 33979991; PMCID: PMC8485659.

Gaël Roué, as corresponding author of the above-referenced article, declares that the request for an addition of a new affiliation for one of the authors (M. Armengol) has been approved by all co-authors. This modification is a prerequisite of Barcelona Autonomous University’s Doctorate program to enable the inclusion of this work in the doctoral thesis of M. Armengol.

*The author and affiliation information should be indicated as follows:*

Ivan Dlouhy,<sup>1,2\*</sup> Marc Armengol,<sup>3,4\*</sup> Clara Recasens-Zorzo,<sup>2</sup> Marcelo L Ribeiro,<sup>3,5</sup> Patricia Pérez-Galán,<sup>2</sup> Francesc Bosch,<sup>6</sup> Armando López-Guillermo<sup>1,2#</sup> and Gaël Roué<sup>3#</sup>

<sup>1</sup>Department of Hematology, Hospital Clínic, Barcelona, Spain; <sup>2</sup>Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain; <sup>3</sup>Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain; <sup>4</sup>Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain <sup>5</sup>Post Graduate Program in Health Science, Universidade São Francisco (USF), Bragança Paulista, Brazil and <sup>6</sup>Laboratory of Experimental Hematology, Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.